209 related articles for article (PubMed ID: 31262571)
1. Gut microbiota in PSC : From association to possible causality. Commentary to "Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis" by Nakamoto et al., Nature Microbiology, January 2019.
Lemoinne S; Sabino J; Sokol H
Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):123-125. PubMed ID: 31262571
[TBL] [Abstract][Full Text] [Related]
2. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis.
Nakamoto N; Sasaki N; Aoki R; Miyamoto K; Suda W; Teratani T; Suzuki T; Koda Y; Chu PS; Taniki N; Yamaguchi A; Kanamori M; Kamada N; Hattori M; Ashida H; Sakamoto M; Atarashi K; Narushima S; Yoshimura A; Honda K; Sato T; Kanai T
Nat Microbiol; 2019 Mar; 4(3):492-503. PubMed ID: 30643240
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome in primary sclerosing cholangitis: A review.
Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the Gut Microbiota and Mycobiota in Italian Pediatric Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis.
Del Chierico F; Cardile S; Baldelli V; Alterio T; Reddel S; Bramuzzo M; Knafelz D; Lega S; Bracci F; Torre G; Maggiore G; Putignani L
Inflamm Bowel Dis; 2024 Apr; 30(4):529-537. PubMed ID: 37696680
[TBL] [Abstract][Full Text] [Related]
5. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.
Sabino J; Vieira-Silva S; Machiels K; Joossens M; Falony G; Ballet V; Ferrante M; Van Assche G; Van der Merwe S; Vermeire S; Raes J
Gut; 2016 Oct; 65(10):1681-9. PubMed ID: 27207975
[TBL] [Abstract][Full Text] [Related]
6. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis.
Lemoinne S; Kemgang A; Ben Belkacem K; Straube M; Jegou S; Corpechot C; ; Chazouillères O; Housset C; Sokol H
Gut; 2020 Jan; 69(1):92-102. PubMed ID: 31003979
[TBL] [Abstract][Full Text] [Related]
7. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
[TBL] [Abstract][Full Text] [Related]
8. Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value.
Li ZJ; Gou HZ; Zhang YL; Song XJ; Zhang L
World J Gastroenterol; 2022 Nov; 28(44):6213-6229. PubMed ID: 36504550
[TBL] [Abstract][Full Text] [Related]
9. Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis.
Lapidot Y; Amir A; Ben-Simon S; Veitsman E; Cohen-Ezra O; Davidov Y; Weiss P; Bradichevski T; Segev S; Koren O; Ben-Ari Z; Safran M
Hepatol Int; 2021 Feb; 15(1):191-201. PubMed ID: 32949377
[TBL] [Abstract][Full Text] [Related]
10. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis.
Bajer L; Kverka M; Kostovcik M; Macinga P; Dvorak J; Stehlikova Z; Brezina J; Wohl P; Spicak J; Drastich P
World J Gastroenterol; 2017 Jul; 23(25):4548-4558. PubMed ID: 28740343
[TBL] [Abstract][Full Text] [Related]
11. Prevotella copri ameliorates cholestasis and liver fibrosis in primary sclerosing cholangitis by enhancing the FXR signalling pathway.
Jiang B; Yuan G; Wu J; Wu Q; Li L; Jiang P
Biochim Biophys Acta Mol Basis Dis; 2022 Mar; 1868(3):166320. PubMed ID: 34896545
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls.
Ostadmohammadi S; Azimirad M; Houri H; Naseri K; Javanmard E; Mirjalali H; Yadegar A; Sadeghi A; Asadzadeh Aghdaei H; Zali MR
Mol Biol Rep; 2021 Jul; 48(7):5519-5529. PubMed ID: 34304365
[TBL] [Abstract][Full Text] [Related]
13. Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts.
Özdirik B; Schnabl B
Cell Mol Gastroenterol Hepatol; 2024; 17(3):423-438. PubMed ID: 38109970
[TBL] [Abstract][Full Text] [Related]
14. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis.
Liu Q; Li B; Li Y; Wei Y; Huang B; Liang J; You Z; Li Y; Qian Q; Wang R; Zhang J; Chen R; Lyu Z; Chen Y; Shi M; Xiao X; Wang Q; Miao Q; Fang JY; Gershwin ME; Lian M; Ma X; Tang R
Gut; 2022 May; 71(5):899-909. PubMed ID: 34035120
[TBL] [Abstract][Full Text] [Related]
15. Manipulation of the Gut-Liver Axis Using Microbiome Restoration Therapy in Primary Sclerosing Cholangitis.
Bajaj JS; Hays RA
Am J Gastroenterol; 2019 Jul; 114(7):1027-1029. PubMed ID: 30920413
[TBL] [Abstract][Full Text] [Related]
16. The gut microbial influence on cholestatic liver disease.
Kummen M; Hov JR
Liver Int; 2019 Jul; 39(7):1186-1196. PubMed ID: 31125502
[TBL] [Abstract][Full Text] [Related]
17. Intestinal microbiota in biliary diseases.
Xia Q; Liu Q; Ma X
Curr Opin Gastroenterol; 2023 Mar; 39(2):95-102. PubMed ID: 36821457
[TBL] [Abstract][Full Text] [Related]
18. The microbiota and the gut-liver axis in primary sclerosing cholangitis.
Hov JR; Karlsen TH
Nat Rev Gastroenterol Hepatol; 2023 Mar; 20(3):135-154. PubMed ID: 36352157
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
Shah A; Macdonald GA; Morrison M; Holtmann G
Am J Gastroenterol; 2020 Jun; 115(6):814-822. PubMed ID: 32250997
[TBL] [Abstract][Full Text] [Related]
20. The Gut-Liver Axis in Primary Sclerosing Cholangitis: Are Pathobionts the Missing Link?
O'Hara SP; LaRusso NF
Hepatology; 2019 Sep; 70(3):1058-1060. PubMed ID: 31013359
[No Abstract] [Full Text] [Related]
[Next] [New Search]
